Hair repigmentation during immunotherapy treatment with an antiâprogrammed cell death 1 and antiâprogrammed cell death ligand 1 agent for lung cancer
JAMA Dermatology Nov 12, 2017
Rivera N, et al. - For the first time, the experts described a new adverse event occurring during antiÂprogrammed cell death 1 (antiÂPD-1)/antiÂprogrammed cell death ligand 1 (antiÂPD-L1 ) therapy for lung cancer (LC). Among patients receiving anti-PD1/antiÂPD-L1 therapy for LC, hair repigmentation could be a good response marker.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
